Glow Peptide (GHK-Cu):
A Research Overview

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is one of the most researched copper-binding peptides in the biomedical literature, with over 2,000 PubMed citations. Its unique high-affinity copper-binding mechanism drives broad regulatory effects on collagen synthesis, wound healing, angiogenesis, and gene expression.

What is GHK-Cu?

GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) isolated from human plasma, saliva, and urine. First identified in 1973 by Dr. Loren Pickart, the peptide was shown to be responsible for the wound-healing and tissue-repairing activity of human albumin. GHK binds Cu(II) with exceptionally high affinity (Kd ~10⁻¹⁵ M), forming a stable planar complex that is recognised by cellular copper transport systems.

GHK-Cu is found in human plasma at ~200 ng/mL in healthy young adults, declining to ~80 ng/mL by age 60 — a decrease of approximately 60%. This age-related decline correlates with reduced wound healing capacity, decreased collagen synthesis, and diminished tissue regeneration in older individuals.

Known Mechanism of Action

Copper Delivery and Metallochaperone Activity

GHK's primary function is to deliver copper (an essential catalytic cofactor) to copper-dependent enzymes. The high-affinity GHK-Cu complex is recognised by membrane copper transporters (CTR1), enabling copper influx into cells. This delivers copper to Cu/Zn superoxide dismutase (SOD-1), cytochrome c oxidase (Complex IV), lysyl oxidase (crosslinking collagen/elastin), and other cuproenzymes essential for tissue metabolism.

Collagen and ECM Gene Expression

GHK-Cu upregulates expression of collagen genes (COL1A1, COL3A1, COL4A1) in fibroblasts through activation of the TGF-β/Smad signalling pathway. It also increases decorin and versican expression (proteoglycans essential for ECM organisation) and decreases MMP-1 activity (collagenase), shifting the balance toward collagen deposition and matrix stabilisation.

Angiogenesis and Wound Healing

Research demonstrates GHK-Cu promotes angiogenesis through VEGF upregulation and endothelial cell migration. In wound healing models, GHK-Cu accelerates re-epithelialisation through increased keratinocyte migration and proliferation — effects mediated by integrin activation and FAK phosphorylation.

Antioxidant and Anti-Inflammatory

GHK-Cu upregulates SOD-1, catalase, and glutathione peroxidase — forming an enhanced antioxidant defence system. It also modulates the NF-κB pathway, reducing TNF-α and IL-1β production. These combined effects reduce oxidative stress and inflammation at wound sites.

Research Applications

• Dermal Tissue: Improved wound closure, collagen density, and reduced scarring in full-thickness wound models.
• Tendon Repair: Collagen fibril diameter, alignment, and tensile strength in Achilles tendon transection models.
• Bone Healing: GHK-Cu accelerates callus formation and mineralisation in tibial fracture models.
• Gastrointestinal Mucosa: Peptic ulcer models show enhanced re-epithelialisation.

Research Protocols

Subcutaneous injection at 1–2 mg/day divided every 12 hours for 4–6 weeks is typical for systemic protocols. Topical administration at 1–10 µM GHK-Cu in saline or hydrogel is standard for dermal research. GHK-Cu is water-soluble and reconstitutes readily in bacteriostatic water or saline.

---